BioCentury | Apr 24, 2020
Product Development

Behind SAB’s rapid response to COVID-19

SAB had already been working with the U.S. Department of Defense to prepare its human polyclonal antibody platform for rapid responses to new infectious diseases when COVID-19 emerged. The company has since applied its DiversitAb...
BioCentury | Feb 28, 2020
Product Development

WHO reports China making 1.6M COVID-19 diagnostic kits per week, describes therapy and vaccine R&D priorities

A WHO report on a Feb. 16-24 mission to China to assess the COVID-19 outbreak summarizes the situation on the ground, highlights countermeasure R&D initiatives, challenges and needs, and identifies critical knowledge gaps. What stands...
BioCentury | Jan 31, 2020
Product Development

CSL is harnessing its supply chain expertise to expand into cell and gene therapy

CSL aims to leverage the logistics expertise it built through its plasma business to expand into cell and gene therapy. The company has a sickle cell disease program in Phase I and is lining up...
BC Week In Review | Nov 2, 2018
Clinical News

Grifols' AMBAR approach slows disease progression in moderate Alzheimer’s

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) reported Phase IIb/III data on its AMBAR approach to treat Alzheimer’s disease demonstrating evidence of mechanism and improvements in clinical outcomes. AMBAR, which stands for Alzheimer Management by Albumin Replacement, was...
BC Extra | Oct 29, 2018
Clinical News

Grifols' AMBAR approach slows disease progression in moderate Alzheimer’s

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) reported Phase IIb/III data on its AMBAR approach to treat Alzheimer’s disease demonstrating evidence of mechanism and improvements in clinical outcomes. AMBAR, which stands for Alzheimer Management by Albumin Replacement, was...
BC Week In Review | Oct 19, 2018
Clinical News

FDA accepts resubmitted BLA for ADMA's RI-002

FDA accepted for review a resubmitted BLA from ADMA Biologics Inc. (NASDAQ:ADMA) for RI-002 to treat primary immune deficiency disease. The PDUFA date is April 2, 2019. In 2016, FDA issued a complete response letter...
BC Week In Review | Oct 5, 2018
Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
BC Extra | Oct 1, 2018
Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
BC Innovations | Aug 8, 2018
Emerging Company Profile

Catching antibodies with polymers

Polyneuron Pharmaceuticals AG's glycopolymers act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies. Polyneuron's Antibody-Catch platform generates glycopolymers...
BC Week In Review | Mar 30, 2018
Company News

Therapure Biopharma spins out Evolve Biologics

Therapure Biopharma Inc. (Mississauga, Ontario) spun out its plasma products and technology division as Evolve Biologics Inc. (Mississauga, Ontario). Evolve emerges with PlasmaCap EBA technology which is used to improve the yields of plasma-based proteins....
Items per page:
1 - 10 of 67